ArticleHepatology (Baltimore, Md.)2010

A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis.

Pradyumna Phatak et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.